RIGL vs. RGLS, MACK, GTHX, EBS, BOLT, XOMA, VNDA, VSTM, LXRX, and GOSS
Should you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Regulus Therapeutics (RGLS), Merrimack Pharmaceuticals (MACK), G1 Therapeutics (GTHX), Emergent BioSolutions (EBS), Bolt Biotherapeutics (BOLT), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical preparations" industry.
Regulus Therapeutics (NASDAQ:RGLS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.
Regulus Therapeutics has a net margin of 0.00% compared to Regulus Therapeutics' net margin of -16.45%. Regulus Therapeutics' return on equity of 0.00% beat Rigel Pharmaceuticals' return on equity.
Rigel Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Regulus Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
Regulus Therapeutics received 30 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. However, 68.85% of users gave Rigel Pharmaceuticals an outperform vote while only 63.54% of users gave Regulus Therapeutics an outperform vote.
Regulus Therapeutics currently has a consensus price target of $7.25, indicating a potential upside of 255.39%. Rigel Pharmaceuticals has a consensus price target of $5.81, indicating a potential upside of 512.16%. Given Regulus Therapeutics' higher possible upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Regulus Therapeutics.
In the previous week, Regulus Therapeutics and Regulus Therapeutics both had 2 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 0.61 beat Regulus Therapeutics' score of -0.09 indicating that Regulus Therapeutics is being referred to more favorably in the media.
92.4% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 4.4% of Regulus Therapeutics shares are owned by insiders. Comparatively, 9.0% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Regulus Therapeutics and Rigel Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Rigel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rigel Pharmaceuticals Competitors List
Related Companies and Tools
